Table 3.
Secondary outcomes.
| Variable | Time Point | No. of Studies | No. of Patients | RR (95% CI) | Within-Group Heterogeneity (I2) |
|---|---|---|---|---|---|
| Survival Rate | 1-year | 4 | MWA: 387 RFA: 364 |
1.05 (0.96–1.15) | 81% |
| 2-year | 3 | MWA: 184 RFA: 164 |
1.03 (0.89–1.18) | 14% | |
| 3-year | 2 | MWA: 250 RFA: 246 |
0.99 (0.91–1.09) | 0% | |
| 5-year | 2 | MWA: 250 RFA: 246 |
0.91 (0.81–1.03) | 0% | |
| Disease-Free survival Rate | 1-year | 6 | MWA: 407 RFA: 403 |
1.00 (0.96–1.04) | 0% |
| 2-year | 4 | MWA: 220 RFA: 200 |
0.94 (0.84–1.06) | 0% | |
| 3-year | 2 | MWA: 250 RFA: 246 |
1.06 (0.93–1.21) | 0% | |
| 5-year | 2 | MWA: 250 RFA: 246 |
3.66 (1.32–42.27) | 69% | |
| Recurrence | Local Recurrence Rate | 6 | MWA: 426 RFA: 402 |
0.70 (0.43–1.14) | 27% |
| Distant Recurrence Rate | 3 | MWA: 116 RFA: 93 |
0.60 (0.39–0.92) | 0% | |
| Adverse Events | Adverse Event Rate | 7 | MWA: 473 RFA: 448 |
1.06 (0.48–2.34) | 13% |
| Variable | No. of Studies | No. of patients | Mean Difference (95% CI) | Within-Group Heterogeneity (I2) | |
| Number of Sessions | 6 | MWA: 407 RFA: 403 |
0.08 (−0.07 to 0.23) | 92% | |
Abbreviation: CI, confidence interval; RR, risk ratio.